In last trading session, Cogent Biosciences, Inc. (NASDAQ:COGT) saw 434,524 shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $8.5 trading at -$0.58 or -6.39% at ring of the bell on the day assigns it a market valuation of $316.15 Million. That closing price of COGT’s stock is at a discount of -75.06% from its 52-week high price of $14.88 and is indicating a premium of 86.12% from its 52-week low price of $1.18. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 194.6 Million shares which gives us an average trading volume of 416.32 Million if we extend that period to 3-months.
For Cogent Biosciences, Inc. (COGT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.3. Splitting up the data highlights that, out of 6 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 6 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.41 in the current quarter.
In the face of being in the red during last session for losing -6.39%, in the last five days COGT remained trading in the green while hitting it’s week-highest on Friday, Apr 16 when the stock touched $9.25-8 price level, adding 8.11% to its value on the day. Cogent Biosciences, Inc.’s shares saw a change of -24.31% in year-to-date performance and have moved 2.53% in past 5-day. Cogent Biosciences, Inc. (NASDAQ:COGT) showed a performance of -4.39% in past 30-days. Number of shares sold short was 2.82 Million shares which calculate 0.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $20.67 to the stock, which implies a rise of 143.18% to its current value. Analysts have been projecting $15 as a low price target for the stock while placing it at a high target of $24. It follows that stock’s current price would jump +182.35% in reaching the projected high whereas dropping to the targeted low would mean a loss of 76.47% for stock’s current value.
Cogent Biosciences, Inc. (COGT) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2021, company’s earnings growth rate is likely to be around -287.1% while estimates for its earnings growth in next 5 years are of 0%
Cogent Biosciences, Inc. (NASDAQ:COGT)’s Major holders
Insiders are in possession of 7.59% of company’s total shares while institution are holding 92.14% percent of that, with stock having share float percentage of 99.71%. Investors also watch the number of corporate investors in a company very closely, which is 82 institutions for Cogent Biosciences, Inc. that are currently holding shares of the company. Perceptive Advisors Llc is the top institutional holder at COGT for having 3.19 Million shares of worth $35.81 Million. And as of December 30, 2020, it was holding 8.57% of the company’s outstanding shares.
The second largest institutional holder is Logos Global Management LP, which was holding about 1.92 Million shares on December 30, 2020. The number of shares represents firm’s hold over 5.16% of outstanding shares, having a total worth of $21.57 Million.
Even if you’re not actively in crypto, you deserve to know what’s actually going on…
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
On the other hand, Invesco Health Care Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of January 30, 2021, the former fund manager was holding 508365 shares of worth $4.46 Million or 1.37% of the total outstanding shares. The later fund manager was in possession of 439.36 Thousand shares on December 30, 2020, making its stake of worth around $4.93 Million in the company or a holder of 1.18% of company’s stock.